United States securities and exchange commission logo





                               August 6, 2020

       Glenn E. Martin
       Chief Executive Officer
       WEED, Inc.
       4920 N. Post Trail
       Tucson, AZ 85750

                                                        Re: WEED, Inc.
                                                            Amendment No. 1 to
Offering Statement on Form 1-A
                                                            Filed July 15, 2020
                                                            File No. 024-11152

       Dear Mr. Martin:

             We have reviewed your amended offering statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your offering statement
and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your offering statement and the
information you
       provide in response to these comments, we may have additional comments.
Unless we note
       otherwise, our references to prior comments are to comments in our March
10, 2020 letter.

       Amendment No. 1 to Offering Statement on Form 1-A, filed July 15, 2020

       Part II - Offering Circular
       Offering Circular Cover Page, page 1

   1.                                                   We note your revised
disclosure in response to comment 2, and it appears that certain
                                                        investors will have the
opportunity to purchase shares at different discounted prices
                                                        depending on when they
invest in your offering. It appears that this may result in shares
                                                        being sold at different
prices at the same time, or "at other than a fixed price," which is not
                                                        permitted under
Regulation A. See Rule 251(d)(3)(ii).
 Glenn E. Martin
FirstName
WEED, Inc.LastNameGlenn E. Martin
Comapany
August     NameWEED, Inc.
       6, 2020
August
Page 2 6, 2020 Page 2
FirstName LastName
Description of Business
Cannabis Genomic Study
The Research Plan, page 28

2.       We note your response to comment 6, and your amended disclosure.
However, your
         amended disclosure is not completely responsive to our comment. To
provide a balanced
         disclosure for investors, please include risk factor disclosure
regarding the risk that you
         may not be able to complete the research and clinical human trials
described in your
         research plan. This risk factor disclosure should include the clinical
trials to which you
         refer in all phases of your research plan, and not only your Sangre
study.
Part III - Exhibits, page 43

3.       We note your response to comment 10, including that the Form of
Securities Purchase
         Agreement referenced in the Original Filing is not the one that will
be used in this
         offering. In this regard, please file the subscription agreement that
will be used in this
         offering as an exhibit to your registration statement. See Item 17.4
of Form 1-A.
      Please contact Katherine Bagley at (202) 551-2545 or Jennifer
Lopez-Molina at (202)
551-3792 with any questions.



                                                                Sincerely,

                                                                Division of
Corporation Finance
                                                                Office of Trade
& Services